Literature DB >> 11895439

Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies.

Nikos G Oikonomakos1, Magda Kosmopoulou, Spyros E Zographos, Demetres D Leonidas, Evangelia D Chrysina, László Somsák, Veronika Nagy, Jean-Pierre Praly, Tibor Docsa, Béla Tóth, Pál Gergely.   

Abstract

Two substituted ureas of beta-D-glucose, N-acetyl-N'-beta-D-glucopyranosyl urea (Acurea) and N-benzoyl-N'-beta-D-glucopyranosyl urea (Bzurea), have been identified as inhibitors of glycogen phosphorylase, a potential target for therapeutic intervention in type 2 diabetes. To elucidate the structural basis of inhibition, we determined the structure of muscle glycogen phosphorylase b (GPb) complexed with the two compounds at 2.0 A and 1.8 A resolution, respectively. The structure of the GPb-Acurea complex reveals that the inhibitor can be accommodated in the catalytic site of T-state GPb with very little change in the tertiary structure. The glucopyranose moiety makes the standard hydrogen bonds and van der Waals contacts as observed in the GPb-glucose complex, while the acetyl urea moiety is in a favourable electrostatic environment and makes additional polar contacts with the protein. The structure of the GPb-Bzurea complex shows that Bzurea binds tightly at the catalytic site and induces substantial conformational changes in the vicinity of the catalytic site. In particular, the loop of the polypeptide chain containing residues 282-287 shifts 1.3-3.7 A (Calpha atoms) to accommodate Bzurea. Bzurea can also occupy the new allosteric site, some 33 A from the catalytic site, which is currently the target for the design of antidiabetic drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895439     DOI: 10.1046/j.1432-1327.2002.02813.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  5 in total

1.  Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.

Authors:  Nikos G Oikonomakos; Magda N Kosmopoulou; Evangelia D Chrysina; Demetres D Leonidas; Ioannis D Kostas; K Ulrich Wendt; Thomas Klabunde; Elisabeth Defossa
Journal:  Protein Sci       Date:  2005-07       Impact factor: 6.725

2.  Outliers in SAR and QSAR: 4. effects of allosteric protein-ligand interactions on the classical quantitative structure-activity relationships.

Authors:  Ki Hwan Kim
Journal:  Mol Divers       Date:  2022-02-22       Impact factor: 3.364

3.  Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1, 3, 4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site.

Authors:  Evangelia D Chrysina; Magda N Kosmopoulou; Constantinos Tiraidis; Rozina Kardakaris; Nicolas Bischler; Demetres D Leonidas; Zsuzsa Hadady; Laszlo Somsak; Tibor Docsa; Pal Gergely; Nikos G Oikonomakos
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

4.  The binding of beta- and gamma-cyclodextrins to glycogen phosphorylase b: kinetic and crystallographic studies.

Authors:  Nikos Pinotsis; Demetres D Leonidas; Evangelia D Chrysina; Nikos G Oikonomakos; Irene M Mavridis
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

5.  Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors.

Authors:  Ádám Sipos; Eszter Szennyes; Nikolett Éva Hajnal; Sándor Kun; Katalin E Szabó; Karen Uray; László Somsák; Tibor Docsa; Éva Bokor
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.